Development ofTherapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells
针对人急性髓性白血病干细胞的治疗性抗体的开发
基本信息
- 批准号:G1000729/1
- 负责人:
- 金额:$ 253.86万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2010
- 资助国家:英国
- 起止时间:2010 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
目前GtR中并没有所有资助研究的摘要。这通常是因为在提交提案时不需要摘要,但也可能是因为摘要中包含个人详细信息等敏感信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paresh Vyas其他文献
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
- DOI:
10.1182/blood-2022-166918 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Connor Sweeney;Gerda Mickute;Kinam Gupta;Marlen Metzner;Batchimeg Usukhbayar;Maria Chiara Barbanti;Gavinda Sangha;Ronjon Chakraverty;Persephone Borrow;Nicola Ternette;Ane Ogbe;Maria Aggelakopoulou;Paresh Vyas - 通讯作者:
Paresh Vyas
Induction of a CD8+ T Cell Response to Tumor Antigens Is Associated with Improved Survival in Patients Transplanted for Acute Myeloid Leukemia
- DOI:
10.1016/j.bbmt.2013.12.247 - 发表时间:
2014-02-01 - 期刊:
- 影响因子:
- 作者:
Sandeep Nagra;Oliver Charles Goodyear;Josephine Khan;Nadira Yasmin Jilani;Paul Ferguson;Nigel Russell;Mike Dennis;Paresh Vyas;Shamyla Siddique;Charles Craddock - 通讯作者:
Charles Craddock
Poster: MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
- DOI:
10.1016/s2152-2650(21)01449-x - 发表时间:
2021-09-01 - 期刊:
- 影响因子:
- 作者:
Guillermo Garcia-Manero;Naval Daver;Jin Xu;Mark Chao;Trisha Chung;Anderson Tan;Yan Wang;Andrew Wei;Paresh Vyas;David Sallman - 通讯作者:
David Sallman
Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed emIDH2/em-Mutated Acute Myeloid Leukemia (AML)
与新诊断的 emIDH2/em 突变急性髓系白血病(AML)中依那西普(ENA)联合阿扎胞苷(AZA)治疗反应相关的分子特征
- DOI:
10.1182/blood-2022-158967 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:23.100
- 作者:
Alberto Risueño;Wendy L. See;Courtney D. DiNardo;Hartmut Döhner;Eytan Stein;Amir T. Fathi;Paresh Vyas;Lynn Quek;Thomas Prebet;Anita K. Gandhi;Maroof Hasan - 通讯作者:
Maroof Hasan
Phenotypic screening identifies a trisubstituted imidazo[1,2-ema/em]pyridine series that induces differentiation in multiple AML cell lines
表型筛选鉴定出一个三取代咪唑并[1,2-ema/em]吡啶系列,可诱导多种急性髓系白血病细胞系分化
- DOI:
10.1016/j.ejmech.2023.115509 - 发表时间:
2023-10-05 - 期刊:
- 影响因子:5.900
- 作者:
Laia Josa-Culleré;Sébastien R.G. Galan;Thomas J. Cogswell;Thomas R. Jackson;Morgan Jay-Smith;Laura Mola;Christopher R. Greaves;Tom S. Carter;Katrina S. Madden;Sophie Trott;Douzi Zhang;Carole J.R. Bataille;Stephen G. Davies;Paresh Vyas;Thomas A. Milne;Alan Naylor;Graham M. Wynne;Angela J. Russell - 通讯作者:
Angela J. Russell
Paresh Vyas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paresh Vyas', 18)}}的其他基金
Biology and Treatment of Human Myeloid Cancers
人类骨髓癌的生物学和治疗
- 批准号:
MC_UU_00029/8 - 财政年份:2022
- 资助金额:
$ 253.86万 - 项目类别:
Intramural
Identification, characterisation and therapeutic targeting of leukaemic stem/propagating cells in Acute Myeloid Leukaemia
急性髓系白血病白血病干细胞/增殖细胞的鉴定、表征和治疗靶向
- 批准号:
MC_UU_00016/11 - 财政年份:2017
- 资助金额:
$ 253.86万 - 项目类别:
Intramural
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours).
人源化抗 CD47 抗体针对急性骨髓性白血病(和实体瘤)癌症干细胞的临床研究。
- 批准号:
MR/L008963/1 - 财政年份:2015
- 资助金额:
$ 253.86万 - 项目类别:
Research Grant
相似海外基金
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
用于靶向治疗的纳米技术和对三阴性乳腺癌治疗耐药性的基本了解
- 批准号:
10593921 - 财政年份:2020
- 资助金额:
$ 253.86万 - 项目类别:
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
用于靶向治疗的纳米技术和对三阴性乳腺癌治疗耐药性的基本了解
- 批准号:
10376777 - 财政年份:2020
- 资助金额:
$ 253.86万 - 项目类别: